Dosing & Uses
Dosage Forms & Strengths
Clarinex-D 12 hr: 1 tablet (2.5 mg desloratadine/120 mg pseudoephedrine) PO q12hr
Clarinex-D 24 hr: 1 tablet (5 mg desloratadine/240 mg pseudoephedrine) PO q24hr
Tablet should be swallowed whole and not broken, dissolved, or chewed
Dosage Forms & Strengths
- Safety and efficacy not established
- Clarinex-D 12 hr: 1 tablet (2.5 mg desloratadine/120 mg pseudoephedrine) PO q12hr
- Clarinex-D 24 hr: 1 tablet (5 mg desloratadine/240 mg pseudoephedrine) PO qDay
Tablet should be swallowed whole and not broken, dissolved or chewed
Serious - Use Alternative
Significant - Monitor Closely
- Fever (12%)
- Irritability (12%)
- Headache (12%)
- Diarrhea (15-21%)
- Cough (11%)
- Upper respiratory tract infection (11-21%)
- Pharyngitis (4.1%)
- Dry mouth (3%)
- Myalgia (2.1%)
- Emotional lability (3%)
- Erythema (3%)
- Macopapular rash (3%)
- Dizziness (4%)
- Fatigue (2.1%)
- Somnolence (2.1%)
- Urinary tract infection (4%)
- Dyspepsia (3%)
- Insomnia (5%)
- Dysmenorrhea (2.1%)
Frequency Not Defined
- CNS (tremor, restlessness, etc)
- Ischemic colitis
Hypersensitivity reactions (eg, rash, edema, dyspnea, anaphylaxis)
CNS: Headache, somnolence, dizziness
eurologic: Movement disorders (including dystonia, tics, and extrapyramidal symptoms), seizures
Hepatic: Elevated liver enzymes and bilirubin, hepatitis (rare)
Hypersensitivity; adverse reaction to sympathomimetics
Severe HTN, severe coronary artery disease
Concurrent MAO inhibitors, or within 2 wk of discontinuance of MAO inhibitors
Clarinex-D 12 hr: also renal impairment
Caution in renal impairment, HTN, diabetes mellitus, ischemic heart disease, increase IOP, hyperthyroidism, BPH
Concomitant antihistamines or decongestants (generally avoid)
Seizures and tachycardia reported
Pregnancy & Lactation
Pregnancy Category: C
Lactation: both drugs pass into breast milk, pseudoephedrine is concentrated in breast milk; use caution
A:Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.
B:May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.
C:Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.
D:Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.
X:Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.
NA:Information not available.
Mechanism of Action
Pseudoephedrine: Sympathomimetic; exerts decongestant action on nasal mucosa; stimulates the alpha-adrenergic receptors causing bronchodilation and vasoconstriction
Desloratadine: Selective histamine-1 receptor antagonist; inhibits histamine release from mast cells
Peak Plasma Time
Pseudoephedrine: 6-9 hr
Desloratadine: 4-7 hr
Peak Plasma Concentration
Pseudoephedrine: 363 ng/mL
Desloratadine: 1.09 ng/mL
Pseudoephedrine: 4,588 ng·hr/mL
Desloratadine: 31.6 ng·hr/mL
Pseudoephedrine: <1% metabolized in liver
Desloratadine: major metabolite of loratadine; extensively metabolized by glucuronidation to active metabolite 3-hydroxydesloratadine
Pseudoephedrine: 3-6 hr (urine pH 5); 9-16 hr (urine pH 8)
Desloratadine: 27 hr
Adding plans allows you to compare formulary status to other drugs in the same class.
To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.
Adding plans allows you to:
- View the formulary and any restrictions for each plan.
- Manage and view all your plans together – even plans in different states.
- Compare formulary status to other drugs in the same class.
- Access your plan list on any device – mobile or desktop.
The above information is provided for general informational and educational purposes only. Individual plans may vary and formulary information changes. Contact the applicable plan provider for the most current information.
|1||This drug is available at the lowest co-pay. Most commonly, these are generic drugs.|
|2||This drug is available at a middle level co-pay. Most commonly, these are "preferred" (on formulary) brand drugs.|
|3||This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs.|
|4||This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.|
|5||This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.|
|6||This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.|
|NC||NOT COVERED – Drugs that are not covered by the plan.|
Drugs that require prior authorization. This restriction requires that specific clinical criteria be met prior to the approval of the prescription.
Drugs that have quantity limits associated with each prescription. This restriction typically limits the quantity of the drug that will be covered.
Drugs that have step therapy associated with each prescription. This restriction typically requires that certain criteria be met prior to approval for the prescription.
Drugs that have restrictions other than prior authorization, quantity limits, and step therapy associated with each prescription.